The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Horizon Discovery and ATCC Sign Global Licensing and Distribution Agreement for X-MAN cell lines

13 Aug 2012

Cambridge, UK, and Manassas, Virginia, 13 August 2012: Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, today announced it has signed a licensing and distribution agreement with the American Type Culture Collection (ATCC) for a select set of panels of X-MAN™ isogenic cell lines. Under the terms of the agreement ATCC will provide Horizon’s products to its academic and not-for-profit customers as a part of or in conjunction with ATCC Tumor Cell Panels, for non-commercial research only. The agreement excludes distribution in Japan or distribution of X-MAN™ isogenic cell lines in isolation.

Horizon’s range of over 450 X-MAN cell lines is the world’s first source of genetically‐defined and patient‐relevant human cell lines, accurately modeling the disease‐causing mutations found in cancer patients. The cell lines were created using the Company’s proprietary and highly precise rAAV gene‐editing technology, GENESIS, with which scientists are able to alter any endogenous gene sequence of a human or mammalian cell line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.

Dr Raymond Cypess, CEO, ATCC, commented: “Horizon’s X-MAN cell line panels are a great complement for ATCC Tumor Cell Panels and will be a valuable resource for our customers. The ability to work with accurate disease model cell lines is of great benefit, particularly in oncology research where many mutations studied are rare, and reliable sources of patient-derived cell lines are scarce.”

“We are delighted that ATCC has chosen to work with us to expand the network of academic and not-for-profit institutions that has access to X-MAN cell lines,” said Dr Darrin Disley, CEO, Horizon. “X-MAN cells are already being widely used by academia and industry to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance. We look forward to seeing the progress in oncology research that increased adoption will bring about.”